Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 05/07 09:43:54 am
463.175 DKK   +1.66%
05/06NOVOTEK AB : Kommuniké från årsstämma
DJ
05/06NOVOTEK AB  : Delårsrapport januari - mars 2021
DJ
05/06NOVO NORDISK  : Credit Suisse reiterates its Neutral rating
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
05/03/2021 05/04/2021 05/05/2021 05/06/2021 05/07/2021 Date
463.4(c) 457.65(c) 459.25(c) 455.6(c) 461.1 Last
3 055 483 2 006 404 3 142 558 1 852 192 863 065 Volume
+2.28% -1.24% +0.35% -0.79% +1.21% Change
More quotes
Financials
Sales 2021 133 B 21 576 M 21 576 M
Net income 2021 44 128 M 7 155 M 7 155 M
Net cash position 2021 8 430 M 1 367 M 1 367 M
P/E ratio 2021 23,7x
Yield 2021 2,13%
Sales 2022 144 B 23 405 M 23 405 M
Net income 2022 48 440 M 7 854 M 7 854 M
Net cash position 2022 12 646 M 2 051 M 2 051 M
P/E ratio 2022 21,1x
Yield 2022 2,34%
Capitalization 1 050 B 170 B 170 B
EV / Sales 2021 7,83x
EV / Sales 2022 7,19x
Nbr of Employees 45 023
Free-Float 74,4%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
05/12Presentation
More about the company
Notations Surperformance© of Novo Nordisk A/S
Trading Rating : Investor Rating :
More Ratings
All news about NOVO NORDISK A/S
05/06NOVOTEK AB : Kommuniké från årsstämma
DJ
05/06NOVOTEK AB  : Delårsrapport januari - mars 2021
DJ
05/06NOVO NORDISK  : Credit Suisse reiterates its Neutral rating
MD
05/06NOVO NORDISK  : Receives a Buy rating from Deutsche Bank
MD
05/06PRESS RELEASE  : Evotec launches 'beLAB1407' to accelerate translational researc..
DJ
05/05NOVO NORDISK A/S  : Posts Higher Q1 Earnings, Lower Sales; Raises 2021 Outlook; ..
MT
05/05NOVO NORDISK : Q1 Earnings Snapshot
AQ
05/05GLOBAL MARKETS LIVE : Lyft, Activision, General Electric...
05/05Novo Nordisk Lifts Guidance and Increases Buybacks -- Earnings Review
DJ
05/05WALL STREET STOCK EXCHANGE : Yellen brings some relief
05/05NOVO NORDISK A/S  : Upgrades Full-Year Sales Guidance After 'Solid' First Quarte..
MT
05/05NOVO NORDISK A/S  : Indicate by check mark whether the registrant files or will ..
PU
05/05TODAY'S ANALYST RECOMMENDATIONS : Qualcomm, 3M, Caterpillar, Paramount, Under Ar..
05/05NOVO NORDISK  : Buy rating from Barclays
MD
05/05NOVO NORDISK  : JP Morgan reiterates its Buy rating
MD
More news
News in other languages on NOVO NORDISK A/S
05/06DGAP-NEWS  : Evotec startet 'beLAB1407' zur -2-
05/05Aktien Europa Schluss: Indizes machen Vortagsrutsch wieder wett
05/05Résumé des principales informations économiques du mercredi 5 mai 2021
05/05DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 05.05.2021 - 15.15 Uhr
05/05MIDDAY BRIEFING - Unternehmen und Märkte -2-
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 2020
A good level to buy
BUY
More Stock Trading Analysis
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 467,87 DKK
Last Close Price 455,60 DKK
Spread / Highest target 22,9%
Spread / Average Target 2,69%
Spread / Lowest Target -25,4%
EPS Revisions
Managers and Directors
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S6.79%170 180
JOHNSON & JOHNSON6.58%441 726
ROCHE HOLDING AG-3.06%284 771
PFIZER, INC.8.58%218 608
ABBVIE INC.8.33%204 861
MERCK & CO., INC.-4.91%196 943